You are here: Industry Insights > Verona Pharma

News List

Enrol call: Verona recruits 800 patients for COPD trial pharmatimes
January 24, 2022
The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed with COPD.
Verona Pharma launches late-stage COPD trial programme pharmatimes
September 27, 2020
Verona Pharma has initiated phase III trials to evaluate the safety and efficacy of nebulised ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Inhaled ensifentrine will be assessed in hospitalised patients pharmatimes
September 08, 2020
Verona Pharma has kicked off a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurised metered-dose inhaler (pMDI) formulation in patients hospitalised with COVID-19.
Verona progresses PhII trial of COPD inhaler pharmatimes
August 19, 2020
Verona Pharma is progressing a Phase II trial of new inhaler formulation of ensifentrine following a coronavirus pandemic-induced pause.
Verona Pharma begins dosing RPL554 in Phase IIb COPD trial pharmatimes
July 27, 2017
Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease